These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26577700)

  • 1. Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
    Herkert B; Kauffmann A; Mollé S; Schnell C; Ferrat T; Voshol H; Juengert J; Erasimus H; Marszalek G; Kazic-Legueux M; Billy E; Ruddy D; Stump M; Guthy D; Ristov M; Calkins K; Maira SM; Sellers WR; Hofmann F; Hall MN; Brachmann SM
    Cancer Res; 2016 Jan; 76(2):390-402. PubMed ID: 26577700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
    Deuker MM; Marsh Durban V; Phillips WA; McMahon M
    Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
    Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
    J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
    Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
    PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
    Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
    PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
    Krepler C; Xiao M; Samanta M; Vultur A; Chen HY; Brafford P; Reyes-Uribe PI; Halloran M; Chen T; He X; Hristova D; Liu Q; Samatar AA; Davies MA; Nathanson KL; Fukunaga-Kalabis M; Herlyn M; Villanueva J
    Oncotarget; 2016 Nov; 7(44):71211-71222. PubMed ID: 27655717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
    Leung GP; Feng T; Sigoillot FD; Geyer FC; Shirley MD; Ruddy DA; Rakiec DP; Freeman AK; Engelman JA; Jaskelioff M; Stuart DD
    Mol Cancer Res; 2019 Jan; 17(1):199-211. PubMed ID: 30201825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.
    Marchetti P; Trinh A; Khamari R; Kluza J
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):999-1005. PubMed ID: 29413908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN regulates IGF-1R-mediated therapy resistance in melanoma.
    Wang J; Sinnberg T; Niessner H; Dölker R; Sauer B; Kempf WE; Meier F; Leslie N; Schittek B
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):572-89. PubMed ID: 26112748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
    Fedorenko IV; Abel EV; Koomen JM; Fang B; Wood ER; Chen YA; Fisher KJ; Iyengar S; Dahlman KB; Wargo JA; Flaherty KT; Sosman JA; Sondak VK; Messina JL; Gibney GT; Smalley KS
    Oncogene; 2016 Mar; 35(10):1225-35. PubMed ID: 26073081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
    Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
    Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.